Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL376169

CCOC(=O)C(CC)(CC)CC#N.N

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
CYP4F2 P78329 2/20 0.49
CYP4A11 Q02928 2/20 0.49
ALDH1A1 P00352 4/20 0.37
TSHR P16473 1/20 0.37
PKM P14618 3/20 0.34
KDM4E B2RXH2 2/20 0.34
THRB P10828 1/20 0.33
LMNA P02545 1/20 0.33
HSD17B10 Q99714 1/20 0.33
HTT P42858 1/20 0.33
CYP2C9 P11712 1/20 0.33
ALOX15 P16050 1/20 0.32
MGAM O43451 1/20 0.32
GAA P10253 1/20 0.32
SI P14410 1/20 0.32
MGAM2 Q2M2H8 1/20 0.32
SOAT1 P35610 1/20 0.32
MAPT P10636 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6733638 0.98 MEN1 (0.52) MEN1KMT2ACYP4F2CYP4A11ALDH1A1
Ammonia Solution, Strong SCHEMBL8176760 0.83 CYP4F2 (0.59) MEN1KMT2ACYP4F2CYP4A11ALDH1A1
Ammonia Solution, Strong SCHEMBL49875 0.81 CYP4F2 (0.61) MEN1KMT2ACYP4F2CYP4A11ALDH1A1
SCHEMBL21772025 0.80 MEN1 (0.36) MEN1KMT2ACYP4F2CYP4A11ALDH1A1
SCHEMBL11710012 0.79 MEN1 (0.68) MEN1KMT2ACYP4F2CYP4A11ALDH1A1
Bromide SCHEMBL25233680 0.79 CYP4F2 (0.59) MEN1KMT2ACYP4F2CYP4A11ALDH1A1
SCHEMBL15353342 0.79 MEN1 (0.49) MEN1KMT2ACYP4F2CYP4A11ALDH1A1
SCHEMBL15353347 0.79 MEN1 (0.49) MEN1KMT2ACYP4F2CYP4A11ALDH1A1
SCHEMBL444076 0.79 CYP4F2 (0.63) MEN1KMT2ACYP4F2CYP4A11ALDH1A1
SCHEMBL1315228 0.78 CYP4F2 (0.50) MEN1KMT2ACYP4F2CYP4A11ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2076606-B1 2'-TERMINATOR RELATED PYROPHOSPHOROLYSIS ACTIVATED POLYMERIZATION ROCHE DIAGNOSTICS GMBH (DE) 2012-01-25 EP disclosed
US-7928207-B2 use of 2'-terminator nucleotides to effect chain termination; kits; incubating a template nucleic acid with a nucleotide incorporating biocatalyst, and a 2'-terminator nucleotide ROCHE MOLECULAR SYSTEMS, INC (US) 2011-04-19 US disclosed
US-7745125-B2 2′-terminator related pyrophosphorolysis activated polymerization ROCHE MOLECULAR SYSTEMS, INC. (US) 2010-06-29 US disclosed
US-20070219361-A1 Synthesis and compositions of nucleic acids comprising 2'-terminator nucleotides ROCHE MOLECULAR SYSTEMS, INC. (US) 2007-09-20 US disclosed
US-20070154914-A1 2'-Terminator related pyrophosphorolysis activated polymerization ROCHE MOLECULAR SYSTEMS, INC. (US) 2007-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070219361-A1 Synthesis and compositions of nucleic acids comprising 2'-terminator nucleotides RNGTT, POLRMT, NT5C3B MEN1 2904/4885KMT2A 1483/4885CYP4F2 2148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.